Table 6.
Effect of PAR2 and EGFR modulators on TJ integrity and/or transcellular permeability of epithelial or endothelial cells based on literary data.
| Target | Type | Compound | Cell Line | Effect on TJs and/or Transcellular Permeability |
Ref. |
|---|---|---|---|---|---|
| PAR2 | peptidic antagonist | FSLLRY-NH2 | pHNECs | harmful | [121] |
| SLIGRL-NH2 | |||||
| non-peptidic full agonist | AC-55541 | hBMECs | protective | [237] | |
| small molecule antagonist | GB88 | A549 | [235] | ||
| hECs | [236] | ||||
| GB83 | Caco2 | harmful | [234] | ||
| EGFR | tyrosine kinase inhibitor | AG1478 | hCMEC/D3 | protective | [238] |
| Calu-3 | [239] | ||||
| HSC-3 | [240] | ||||
| erlotinib | IEC-6 | harmful | [241] | ||
| gefitinib | [242] | ||||
| icotinib | |||||
| dacomitinib | T84 | [244] | |||
| lapatinib | HBCCs | [245] | |||
| vandetanib | Calu-6 | [246] |
Abbreviations: pHNECs: primary human nasal epithelial cells; hBMECs: human brain microvascular endothelial cells; hECS: primary human arterial endothelial cells; hCMEC: primary human cardiac microvascular endothelial cells; HBBCs: primary human breast cancer epithelial cells.